308 related articles for article (PubMed ID: 15482191)
1. Recent advances in antifungal pharmacotherapy for invasive fungal infections.
Gallagher JC; MacDougall C; Ashley ES; Perfect JR
Expert Rev Anti Infect Ther; 2004 Apr; 2(2):253-68. PubMed ID: 15482191
[TBL] [Abstract][Full Text] [Related]
2. [symbol: see text]Caspofungin and [symbol: see text]voriconazole for fungal infections.
Drug Ther Bull; 2004 Jan; 42(1):5-8. PubMed ID: 14768298
[TBL] [Abstract][Full Text] [Related]
3. Caspofungin: a major breakthrough in treatment of systemic fungal infections.
Agarwal MB; Rathi SA; Ratho N; Subramanian R
J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012
[TBL] [Abstract][Full Text] [Related]
4. [Systemic antifungals. Pharmacodynamics and pharmacokinetics].
Catalán M; Montejo JC
Rev Iberoam Micol; 2006 Mar; 23(1):39-49. PubMed ID: 16499430
[TBL] [Abstract][Full Text] [Related]
5. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
6. Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update.
Wilson DT; Drew RH; Perfect JR
Mycopathologia; 2009 Dec; 168(6):313-27. PubMed ID: 19308672
[TBL] [Abstract][Full Text] [Related]
7. [Antifungal activity and clinical efficacy of liposomal amphotericin B (AmBisome)].
Maniwa T; Yamamoto Y
Nihon Yakurigaku Zasshi; 2007 Feb; 129(2):129-34. PubMed ID: 17299241
[No Abstract] [Full Text] [Related]
8. Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: a review.
Viscoli C; Castagnola E
Int J Infect Dis; 1998-1999 Winter; 3(2):109-18. PubMed ID: 10225990
[TBL] [Abstract][Full Text] [Related]
9. Echinocandins: role in antifungal therapy, 2005.
Zaas AK; Alexander BD
Expert Opin Pharmacother; 2005 Aug; 6(10):1657-68. PubMed ID: 16086652
[TBL] [Abstract][Full Text] [Related]
10. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.
Groll AH; Walsh TJ
Expert Opin Investig Drugs; 2001 Aug; 10(8):1545-58. PubMed ID: 11772269
[TBL] [Abstract][Full Text] [Related]
11. Changing strategies for the management of invasive fungal infections.
Rapp RP
Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
[TBL] [Abstract][Full Text] [Related]
12. Echinocandins: The Expanding Antifungal Armamentarium.
Aguilar-Zapata D; Petraitiene R; Petraitis V
Clin Infect Dis; 2015 Dec; 61 Suppl 6():S604-11. PubMed ID: 26567277
[TBL] [Abstract][Full Text] [Related]
13. The value of amphotericin B in the treatment of invasive fungal infections.
Klepser M
J Crit Care; 2011 Apr; 26(2):225.e1-10. PubMed ID: 20951541
[TBL] [Abstract][Full Text] [Related]
14. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
Viscoli C; Castagnola E
Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
[TBL] [Abstract][Full Text] [Related]
15. Management of systemic fungal infections: alternatives to itraconazole.
Herbrecht R; Nivoix Y; Fohrer C; Natarajan-Amé S; Letscher-Bru V
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i39-i48. PubMed ID: 16120633
[TBL] [Abstract][Full Text] [Related]
16. [Systemic antifungal agents].
Lumbreras C; Lizasoain M; Aguado JM
Enferm Infecc Microbiol Clin; 2003; 21(7):366-79; quiz 380, 390. PubMed ID: 14525693
[TBL] [Abstract][Full Text] [Related]
17. Caspofungin: first approved agent in a new class of antifungals.
Johnson MD; Perfect JR
Expert Opin Pharmacother; 2003 May; 4(5):807-23. PubMed ID: 12740003
[TBL] [Abstract][Full Text] [Related]
18. Caspofungin acetate for treatment of invasive fungal infections.
Pacetti SA; Gelone SP
Ann Pharmacother; 2003 Jan; 37(1):90-8. PubMed ID: 12503942
[TBL] [Abstract][Full Text] [Related]
19. New antifungal agents.
Gupta AK; Tomas E
Dermatol Clin; 2003 Jul; 21(3):565-76. PubMed ID: 12956208
[TBL] [Abstract][Full Text] [Related]
20. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
